Get the facts about safety and side effects
CSU patient portayal.
RHAPSIDO® (remibrutinib) has a proven safety profile
The safety of RHAPSIDO was studied in the largest clinical trials for adults living with CSU and was evaluated at 6 months (868 patients).†
†Based on completed trials for CSU as of September 2025.
The most common side effects seen in clinical trials for CSU
Nasopharyngitis (nasal congestion, sore throat, and runny nose)
11% of those who took RHAPSIDO and 9% who took placebo
Bleeding
9% of those who took RHAPSIDO and 2% who took placebo experienced bleeding
In the CSU clinical trials, of the 9%, the most common were tiny red spots beneath the skin (4%)
Occurred within the first 3 months of treatment
Mostly seen on the arms, legs, neck, or stomach
1 patient (0.2%) in the RHAPSIDO group and no patients in the placebo group stopped treatment
Headache
7% of those who took RHAPSIDO and 6% who took placebo
Nausea
3% of those who took RHAPSIDO and 2% who took placebo
Abdominal pain
3% of those who took RHAPSIDO and 2% who took placebo
These are not all of the possible side effects of RHAPSIDO. View the full Prescribing Information to learn more.
The safety profile of RHAPSIDO in the SD trial was consistent with the safety profile in the CSU trials.